NO115741B - - Google Patents
Download PDFInfo
- Publication number
- NO115741B NO115741B NO160437A NO16043765A NO115741B NO 115741 B NO115741 B NO 115741B NO 160437 A NO160437 A NO 160437A NO 16043765 A NO16043765 A NO 16043765A NO 115741 B NO115741 B NO 115741B
- Authority
- NO
- Norway
- Prior art keywords
- water
- solution
- methanol
- formula
- sodium
- Prior art date
Links
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 16
- 150000001875 compounds Chemical class 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 8
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- 150000001299 aldehydes Chemical class 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- IAJBQAYHSQIQRE-UHFFFAOYSA-N 2,4,5-trimethoxybenzaldehyde Chemical compound COC1=CC(OC)=C(C=O)C=C1OC IAJBQAYHSQIQRE-UHFFFAOYSA-N 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims description 3
- 150000004703 alkoxides Chemical class 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- DNAVOCNYHNNEQI-UHFFFAOYSA-N asaronaldehyde Natural products COC1=CC(OC)=C(C=CC=O)C=C1OC DNAVOCNYHNNEQI-UHFFFAOYSA-N 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims description 3
- LXQRQVUSDOKVLD-UHFFFAOYSA-N 2,4,5-trichlorobenzaldehyde Chemical compound ClC1=CC(Cl)=C(C=O)C=C1Cl LXQRQVUSDOKVLD-UHFFFAOYSA-N 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 72
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 32
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 21
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 19
- 238000010992 reflux Methods 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 238000003756 stirring Methods 0.000 description 12
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 11
- 239000011734 sodium Substances 0.000 description 11
- 229910052708 sodium Inorganic materials 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000000155 melt Substances 0.000 description 9
- 239000013078 crystal Substances 0.000 description 8
- 238000002844 melting Methods 0.000 description 8
- 230000008018 melting Effects 0.000 description 8
- 229960000583 acetic acid Drugs 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 229960004198 guanidine Drugs 0.000 description 7
- 239000000047 product Substances 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- AGIQIOSHSMJYJP-UHFFFAOYSA-N 1,2,4-Trimethoxybenzene Chemical compound COC1=CC=C(OC)C(OC)=C1 AGIQIOSHSMJYJP-UHFFFAOYSA-N 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 150000002825 nitriles Chemical class 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 239000003610 charcoal Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000005292 vacuum distillation Methods 0.000 description 3
- SFPQDYSOPQHZAQ-UHFFFAOYSA-N 2-methoxypropanenitrile Chemical compound COC(C)C#N SFPQDYSOPQHZAQ-UHFFFAOYSA-N 0.000 description 2
- OPHQOIGEOHXOGX-UHFFFAOYSA-N 3,4,5-trimethoxybenzaldehyde Chemical compound COC1=CC(C=O)=CC(OC)=C1OC OPHQOIGEOHXOGX-UHFFFAOYSA-N 0.000 description 2
- OOWFYDWAMOKVSF-UHFFFAOYSA-N 3-methoxypropanenitrile Chemical compound COCCC#N OOWFYDWAMOKVSF-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 229960000654 sulfafurazole Drugs 0.000 description 2
- HZKGTRUEBFRMNO-UHFFFAOYSA-N (3,4,5-trichlorophenyl)methanol Chemical compound OCC1=CC(Cl)=C(Cl)C(Cl)=C1 HZKGTRUEBFRMNO-UHFFFAOYSA-N 0.000 description 1
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 1
- OOLOAWZLPBDRJQ-UHFFFAOYSA-N 2-benzylpyrimidine Chemical class N=1C=CC=NC=1CC1=CC=CC=C1 OOLOAWZLPBDRJQ-UHFFFAOYSA-N 0.000 description 1
- GHMOHPITLLRUAC-UHFFFAOYSA-N 3,4,5-trichlorobenzaldehyde Chemical compound ClC1=CC(C=O)=CC(Cl)=C1Cl GHMOHPITLLRUAC-UHFFFAOYSA-N 0.000 description 1
- DCWQZPJHHVLHSV-UHFFFAOYSA-N 3-ethoxypropanenitrile Chemical compound CCOCCC#N DCWQZPJHHVLHSV-UHFFFAOYSA-N 0.000 description 1
- OXGJKCALURPRCN-UHFFFAOYSA-N 3-methoxypropanal Chemical compound COCCC=O OXGJKCALURPRCN-UHFFFAOYSA-N 0.000 description 1
- RMIZEUOAFVZZJG-UHFFFAOYSA-N 4,5-dimethoxy-2-methylbenzaldehyde Chemical compound COC1=CC(C)=C(C=O)C=C1OC RMIZEUOAFVZZJG-UHFFFAOYSA-N 0.000 description 1
- NHZLNPMOSADWGC-UHFFFAOYSA-N 4-amino-N-(2-quinoxalinyl)benzenesulfonamide Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CN=C(C=CC=C2)C2=N1 NHZLNPMOSADWGC-UHFFFAOYSA-N 0.000 description 1
- FQLKASDBWGNDRZ-UHFFFAOYSA-N 5-[(2,4,5-trichlorophenyl)methyl]pyrimidine-2,4-diamine Chemical compound NC1=NC(N)=NC=C1CC1=CC(Cl)=C(Cl)C=C1Cl FQLKASDBWGNDRZ-UHFFFAOYSA-N 0.000 description 1
- OCPCMYIYGAVFJT-UHFFFAOYSA-N 5-[(3,4,5-trichlorophenyl)methyl]pyrimidine-2,4-diamine Chemical compound NC1=NC(N)=NC=C1CC1=CC(Cl)=C(Cl)C(Cl)=C1 OCPCMYIYGAVFJT-UHFFFAOYSA-N 0.000 description 1
- KEEYRKYKLYARHO-UHFFFAOYSA-N 5-[(4,5-dimethoxy-2-methylphenyl)methyl]pyrimidine-2,4-diamine Chemical compound C1=C(OC)C(OC)=CC(C)=C1CC1=CN=C(N)N=C1N KEEYRKYKLYARHO-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- YSVZGWAJIHWNQK-UHFFFAOYSA-N [3-(hydroxymethyl)-2-bicyclo[2.2.1]heptanyl]methanol Chemical compound C1CC2C(CO)C(CO)C1C2 YSVZGWAJIHWNQK-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 150000002927 oxygen compounds Chemical class 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229940087562 sodium acetate trihydrate Drugs 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- ZZORFUFYDOWNEF-UHFFFAOYSA-N sulfadimethoxine Chemical compound COC1=NC(OC)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ZZORFUFYDOWNEF-UHFFFAOYSA-N 0.000 description 1
- 229960000973 sulfadimethoxine Drugs 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- 229960003097 sulfaquinoxaline Drugs 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- WJUFSDZVCOTFON-UHFFFAOYSA-N veratraldehyde Chemical compound COC1=CC=C(C=O)C=C1OC WJUFSDZVCOTFON-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/30—Halogen atoms or nitro radicals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/137—Heterocyclic compounds containing two hetero atoms, of which at least one is nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Fodder In General (AREA)
Description
Fremgangsmåte for fremstilling av pyrimidinderivater.
Oppfinnelsen vedrører en fremgangsmåte generelle formel for fremstilling av benzylpyrimidiner med den
hvor Rj betyr klor, en methoxygruppe eller
fortrinnsvis hydrogen eller en methylgruppe;
R2 hydrogen, klor eller en methoxygruppe og
R3og R4halogen (klor, brom eller fluor), en methylgruppe eller en lavere alkoxygruppe.
Under lavere alkoxygrupper er å forstå grupper med rettkjedeté eller forgrenete alkylgrupper, som methyl, ethyl, propyl, isopropyl, butyl, hexyl eller heptyl.
Fremgangsmåten ifølge oppfinnelsen kan
gjennomføres etter følgende reaksjonsskjema, hvor symbolene R,—R4har den for forbindelsene med formel I angitte betydning og R og R' betyr lavere alkylgrupper, fortrinnsvis methyl-grupper.
Etter fremgangsmåten ifølge oppfinnelsen omsettes først et aldehyd med formel II med et (3-lavere-alkoxy-propionitril med formel III i nærvær av et lavere alkalialkoxyd, som natrium-methoxyd eller kaliumethoxyd og et lavere alka-nol med formel R'OH som methanol, ethanol eller propanol. Reaksjonstemperaturen er ikke avgjørende, den ligger imidlertid generelt mel-lom 60 og 140°C. Herved oppnås en forbindelse med formel IV. I noen tilfelle dannes først et mellomprodukt med formel IVa
som omdannes lett ved behandling med alkano-len R'OH i nærvær av et lavere alkalialkoxyd under vannfrie betingelser til en forbindelse med formel IV. Også her er reaksjonstemperaturer på ca. 60 til ca. 140° egnet. Forbindelsen med formel IV overføres så med quanldin nesten kvanti-tativt til en forbindelse med formel I.
Aldehydene med formel II er for største de-len kjent eller kan fremstilles etter i og for seg kjente metoder, f. eks. etter Vdlsmeyer-reaksjo-nen [Methoden der organischen Chemie (Hou-ben Weyl 1954) Bind: Sauerstoffverbindungen II, del 1, side 29] eller etter Rosenmund (Migrdi-chien Organic Synthesis II, side 1332).
Fremgangsmåten ifølge oppfinnelsen utmer-ker seg i særdeleshet ved at forbindelsene med formel I kan oppnås i et vesentlig høyere utbytte enn det som var mulig etter de kjente fremgangsmåter, f. eks. de i US-patent nr. 3 049 544.
Forbindelsene med formel I er antibak-terielt virksomme og spesielt egnet for lokale anvendelser. De kan kombineres med antibak-teriell virksomme sulfonamiider, f. eks. med sulfisoxazol, sulfamethoxazol, sulfadimethoxin eller sulfachinoxalin. For oral administrasjon på en voksen består en slik kombinasjon f. eks. av 0,5 g sulfisoxazol og 100 mg av en forbindelse med formel I i en farmasøytisk vanlig ad-ministrasjonsform, som f. eks. tabletter, kaps-ler eller vandige suspensjoner.
Eksempel 1.
Til en blanding av 485 g acetanhydrid og 32 g konsentrert svovelsyre tilsettes i små por-sjoner ved 40—50° i løpet av 45 til 60 minutter 162 g benzochinon. Deretter røres blandingen 30—45 minutter ved 40—50° og avkjøles så til ca. 25°. Reaksjonsblandingen helles på 2,2 liter isvann, det hvite bunnfall filtreres fra og vaskes med kaldt vann. De således erholdte filterkaker av triacetoxybenzol tilsettes til 600 ml methanol, hvorpå blandingen tilsettes 1420 g dimethylsulfat. Man oppnår en klar homogen oppløsning, som tilsettes i løpet av 2y2time en oppløsning av 900 g natriumhydroxyd i 900 ml vann, hvorved reaksjonstemperaturen holdes ved avkjøling med isvann ved 38—44°. Deretter røres 30 minutter ved 40—45°, så oppvarmes 30 minutter under røring under tilbakeløp. Reak-sj onsblandingen står til henstand natten over og så helles på 3 liter kaldt vann. Oppløsningen ekstraheres 4 ganger med hver gang 500 ml benzol, de forente benzoliske oppløsninger vaskes 2 ganger med 200 ml vann, tørkes over natriumsulfat og inndampes i vakuum på vann-badet. 1,2,4-trimethoxybenzolen oppnås ved vakuumdestillering ved 122—124°/8—10 mm)
(128°/12 mm) som klar, fargeløs olje.
101 g 1,2,4-trimethoxybenzol og 55 dime-thylformamid tilsettes i løpet av 30—45 minutter ved 20° under røring 115 g fosforoxyklorid.
Man oppvarmer så, hvorved temperaturen sti-ger spontant til 50—55° og oppvarmer reaksjonsblandingen etter avslutning av spontanre-aksjonen 2y2time til 95°. Etter avkjøling helles reaksjonsblandingen på 500 g isvann og inn-stilles med 200 g natriumacettrihydrat til pH 5. Reaksjonsblandingen røres videre under avkjø-ling med isvann 2 timer, hvorved det danner seg en tykk hvit krystallgrøt, som avsuges og vaskes 2 ganger med 100 ml iskaldt vann. Det rå 2,4,5-trimethoxybenzaldehyd tørkes i vakuum over kalsiumklorid ved værelsestemperatur. Det ved 109—111° smeltende produkt er rent nok for det neste reaksjonstrinn.
En oppløsning av 5,2 g natrium i 260 ml methanol tilsettes 42 g |3-ethoxypropionitril og 42 g 2,4,5-trimethoxybenzaldehyd. Reaksjonsblandingen oppvarmes 12—15 timer under til-bakeløp, lar den avkjøles litt og tilsettes 80 ml av en 40—50 pst.ig methanolisk guanidinopp-løsning (fremstilt ved røring av 61 g guanidin-hydroklowid med en oppløsning av 14,5 g natrium i 200 ml methanol, filtrering og inndampning av filtratet i vakuum under COa-utelukkelse på 80 ml). Reaksjonsblandingen røres 4 timer under tilbakeløp, tilsettes anodekrystaller og røres videre 12 timer under tilbakeløp. Krystallisasjo-nen fullendes ved 24 timers henstand ved 0—5° under C02-utelukkelse. De frafiltrerte krystal-ler oppslemmes med 40 ml kald methanol, filtreres og vaskes i rekkefølge med 20 ml vann,'10 ml methanol og 40 ml ether. Det gullige produkt viser et smp. på 208—210°. For rensing suspenderes 27,5 g av dette råprodukt i 200 ml vann ved 80—90° og tilsattes 10 ml iseddik. Den gule oppløsning avkjøles til 10—15° og tilsettes ytterligere 35 ml iseddik. Krystallene suges fra og vaskes 2 ganger med hver gang 20 ml iskald og 15 pst.ig vandig eddiksyre. Filterkakene opp-løses i 150 ml varmt vann, oppløsningen renses med kull, produktet felles ut med 50 ml 30 pst.ig natriumhydroxydoppløsning, filtreres og vaskes alkalifri med vann. Det således erholdte 2,4-diamiino-5-(2',4',5'-methoxybenzol)pyrimidin
smelter ved 212—213°.
Eksempel 2
62,85 g 2,4,5-triklorobenzaldehyd tilsettes til en blanding av 6,9 g natrium d methanol og 51 g (3-methoxy-propionitril. Reaksjonsblandingen holdes 5 timer under tilbakeløp, tilsettes 60 ml vann og står til henstand natten over ved 0—5°. Krystallene filtreres fra og vaskes med kald 80 pst.ig methanol, hvorved 55 g råprodukt oppnås. Etter krystallisasjon fra methanol oppnår man 2,4,5-tniklor-2'-cyano-2',3'-dihydro-kanel-aldehyd-dimethylacetal i form av hvite nåler, som smelter ved 77—78°.
30,85 g 2,4,5-triklor-2'-cyano-2',3'-dihydro-kanelaldehyd-dlmethylacetal oppvarmes med 200 ml N-metanolisk guanidin-oppløsning 2 timer under røring under tilbakeløp. Methanolen avdestillerer fullstendig, tilslutt ved et oljebad ved 110—120°. Den krystalline rest oppslemmes 1 vann, filtreres fra og vaskes med litt alkohol og ether. Deretter oppløses resten varmt i 120 ml eddiksyre og 350 ml vann, oppløsning renses med kull og filtratet gjøres alkalisk etter av-kjøling med en oppløsning av 100 g natriumhydroxyd i 300 ml vann. Man oppnår 30,5 g 2,4-diiamino-5-(2',4',5'-triklorbenzyl)-pyrimidin, smp. 248°.
Eksempel 3.
40 g 3,4,5-triklorbenzaldehyd, 34 g (3-methoxy-propionaldehyd og en natriummethylatoppløs-ning fra 4,4 g natrium i 100 ml methanol oppvarmes 4 timer under røring under tilbakeløp. Oppløsningen fortynnes med 200 ml vann og ekstraheres med ether. Det etheriske ekstrakt inndampes og fraksjoneres'i vakuum. Etter de-stillering av 10 g 3,4,5-triklorbenzylalkohol, som går over ved 155—170°/11 mm, destilleres 20 g 3,4,5-triklor-2'-cyano-2',3'-dihydrokanelalde-hyd-dimethylacetal ved 195—208°/ll mm, som krystalliserer ved henstand. Preparatet smelter etter omkrystallisasjon fra methanol ved 85— 86°. 15 g rå 3,4,5-triklor-2'-cyano-2',3'-dihydro-kanelaldehyd-dimethylacetal oppvarmes med 100 ml l-n methanolisk guanidin-oppløsning 2 timer under tilbakeløp, deretter avdestilleres opp-løsningsmidlet fullstendig i løpet av ytterligere 2 timer. Den krystalline rest oppslemmes i vann, frafiltreres og overføres for rensing ved behandling med varm 20 pst.ig eddiksyre i acetatet.
Den fra acetatet ved hjelp av overskytende na-triumhydroxydoppløsning frisatte base, 2,4-di-amino-5- (3',4',5'-tiiiklorbenzyl) -pyrimidin, smelter ved 285—286°. Utbytte 13,5 g.
Eksempel 4.
Den fra 6 g natrium og 300 ml methanol erholdte oppløsning tilsettes 47,5 g [3-methoxy-propionitril og 98 g 3,4,5-trlmethoxybenzaldehyd. Reaksjonsblandingen oppvarmes 4 timer under tilbakeløp, deretter avkjøles og tilsettes 150 ml vann. Reaksjonsblandingen får henstå 1 time under røring ved 5—10° for krystallisasjon, der-på filtreres og vaskes med 60 pst.ig iskald methanol. Det ved 78—80° smeltende lufttørkende råmaterial anvendes uten ytterligere rensing. Utbytte 92 g.
En oppløsning av 19 g natrium i 300 ml methanol kokes med 106 g 3,4,5-trimethoxy-2'r methoxymethylkanelsyreniitril 24 timer under tilbakeløp. Oppløsningen helles på 1 liter vann og ekstraheres igjen med benzol. De forente benzoliske ekstrakter (500—700 ml) vaskes 3 ganger med 500 ml vann og inndampes i vakuum. Resten gir ved vakuumdestillasjon 83 g 3.4,5-trimethoxy-2'-cyano-dihydrokanelaldehyd-dimethylacetal, kokepunkt 215—225°/ll mm, n<2>D<3>=1,5230 som klar, viskøs olje, som krystalr Mserer ved henstand. Det fra methanol omkrystalliserte preparat smelter ved 6970°, n<2>D<5>=1,5190.
31,5 g 3,4,5-trimethoxy-2'-cyano-dihydroka-nelaldehyd-dimethylacetal oppvarmes med 200 ml av en methanolisk guanidinoppløsning (0,250 mol guanidin) 2 timer under tilbakeløp. Methanolen avdestilleres fullstendig under røring, hvorved resten størkner til en gullig krystall-masse. Resten oppslemmes etter avkjøling i 100 ml vann, frafiltreres og tørkes og gir 28 g 2,4-diamino-5-(3',4',5'-trimethoxybenzyl)pyrimidin, smeltepunkt 199—200°. 20 g av det foranstående, gullig fargede produkt tilsettes ved 60° under røring til 30 ml 3-n svovelsyre. Oppløsningen avkjøles under rø-ring til 5—10°, krystallsatet frafiltreres og vaskes 2 ganger med hver gang 10 ml kald 3-n svovelsyre. Fra filtratet oppnås 1,3 g farget material med smeltepunkt 195—196°, som— ytterligere kan tilsettes rensingstilsetninger. Det krystalliserte sulfat oppløses i 200 ml varmt vann, oppløsningen behandles med varm kull og produktet felles ut ved tilsetning av en opp-løsning av 20 g natriumhydroxd i 40 ml vann under avkjøling. Man oppnår 17,5 g hvitt 2,4-dlamino-5- (3',4',5'-trimethoxybenzyl) -pyrimi-din med smeltepunkt 200—201°.
Eksempel 5.
166 g veratrumaldehyd og 95 g methoxy-propionitril oppvarmes i en methanolisk na-triummethylatoppløsning (11 g natrium i 400 ml absolutt methanol) 4 timer under røring under tilbakeløp. Oppløsningen krystalliserer ved avkjøling til 0° og inndampnling. Krystallene avfUtreres og vaskes med iskald 60 pst.ig me^
thanol. Man oppnår 147 g lufttørket 3,4-dime-thoxy-2'-methoxymethyl-kanelsyrenitril. Ved fortynning av filtratet med vann, ekstraksjon med benzol og vakuumdestdllering oppnås en annen fraksjon av 35 g. Det fra methanol om-krystalMserte produkt smelter ved75°, n 2U5=1,5862.
180 g 3,4-dimethoxy-2'-methoxymethyl-ka-nelsyrenitril oppvarmes i en methanolisk na-triummethylatoppløsning (37 g natrium i 600 ml absolutt methanol) 24 timer under tilbakeløp. Reaksjonsoppløsndngen helles på 1,5 liter vann og ekstraheres med 500 ml benzol. De benzoliske ekstrakter vaskes på ny med små mengder eddiksyre, som inneholder vann, og inndampes i vakuum. Destillasjon av resten ved 205—210° gir 152 g 3,4-dimethoxy-2'-cyano-dihydrokanel-aldehyd-dimethylacetal som fargeløs olje, som krystalliserer etter noen Md. Det for analyse-formål fra methanol omkrystalliserte preparat smelter ved 50—51°, n2D5=1,5235.
26,5 g 3,4-dlimethoxy-2'-cyano-dihydrokanel-aldehyd-dimethylacetal kokes med 250 ml n-methanolisk guanidinoppløsning 2 timer. Opp-løsningsmidlet avdestilleres fullstendig i løpet av 2 timer. Den krystalline rest oppslemmes i 100 ml vann, filtreres og vaskes med litt alkohol og ether. Man oppnår 24,5 g 2,4-diamino-5-(3', 4'-dimethoxybenzylpyrimlidin, smeltepunkt 233°.
Eksempel 6.
90 g 4,5-dimethoxy-2-methylbenzaldehyd og 50 g methoxypropionitril oppvarmes i en methanolisk natriummethylatoppløsning (5,5 g natrium i 150 ml methanol) 4 timer under røring
under tilbakeløp. Oppløsningen helles på 1 liter vann og ekstraheres med benzol. Den benzoliske oppløsning vaskes med vann, inndampes og resten destilleres ved 200—208°. Man oppnår 103 g 4,5-dimethoxy-2-methyl-2'-methoxymethyl-kanelsyrenitril som gullig olje, som krystalliserer ved henstand. Det fra methanol omkrystalliserte preparat smelter ved 68—69°, n<2>D<5>= 1,5823.
283 g 4,5-dimethoxy-2-methyl-2'-methoxy-methylkanelsyrenitril oppvarmes med en methanolisk natriummethylatoppløsning (53 g natrium i 800 ml absolutt methanol) 24 timer under tilbakeløp. Reaksjonsoppløsningen helles på 1,5 liter vann og ekstraheres med benzol. Ben-zoloppløsningen ekstraheres igjen med vann, som inneholder små mengder eddiksyre, og inndampes i vakuum. Resten destilleres ved 205—211° og gir 250 g 4,5-dimethoxy-2-methyl-2'-cyano-dihydrokanelaldehyd-dimethylacetal, som krystalliserer ved henstand. Det fra methanol omkrystalliserte preparat smelter ved 60—61°,2D<5>= 1, 5228.
55,8 g 4,5-dimethoxy-2-methyl-2'-cyano-di-hydrokanel-aldehyd-dimethylacetal oppvarmes med 250 ml 1 molar methanolisk guanidinoppløs-ning 2 timer under tilbakeløp. Oppløsningsmid-let avdestilleres så fullstendig, den krystalline rest oppslemmes 1 100 ml vann, frafiltreres og vaskes med litt iskald alkohol og ether. Man oppnår 47 g 2,4-diamino-5-(4',5'-dimethoxy-2'-methylbenzyl)pyrimidin, smeltepunkt 233°.
Claims (2)
1. Fremgangsmåte for fremstilling av for-bindelser med den generelle formel I
hvor Rj betyr hydrogen, klor eller en methyl- eller methoxygruppe;
RR2 hydrogen, klor eller en methoxygruppe og
R3 og R4 halogen, en methyl- eller en lavere
alkoxygruppe,
karakterisert ved at man omsetter et aldehyd med den generelle formel II
med en forbindelse med den generelle formel III
hvor R er en lavere alkylgruppe,
i nærvær av et lavere alkalialkoxyd og en alkohol med formel
hvor R' er en lavere alkylgruppe,
under vannfrie betingelser til en forbindelse med den generelle formel IV
og kondenserer forbindelsen med den generelle formel IV med guanidin.
2. Fremgangsmåte ifølge krav 1, karakterisert ved at man som aldehyd med formel II anvender 2,4,5-trimethoxybenzaldehyd eller 2,4,5-triklorbenzaldehyd.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41079364A | 1964-11-12 | 1964-11-12 | |
US41071064A | 1964-11-12 | 1964-11-12 | |
US45416865A | 1965-05-07 | 1965-05-07 | |
US45417265A | 1965-05-07 | 1965-05-07 | |
US46083465A | 1965-06-02 | 1965-06-02 | |
US470917A US3341541A (en) | 1964-11-12 | 1965-07-09 | Processes and intermediates for pyrimidine derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
NO115741B true NO115741B (no) | 1968-11-25 |
Family
ID=27559952
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO160436A NO119948B (no) | 1964-11-12 | 1965-11-11 | |
NO160437A NO115741B (no) | 1964-11-12 | 1965-11-11 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO160436A NO119948B (no) | 1964-11-12 | 1965-11-11 |
Country Status (15)
Country | Link |
---|---|
US (3) | US3485840A (no) |
BE (3) | BE671982A (no) |
BR (3) | BR6574670D0 (no) |
CH (2) | CH467784A (no) |
DE (2) | DE1545966A1 (no) |
DK (2) | DK125553B (no) |
FI (1) | FI43251B (no) |
FR (1) | FR5411M (no) |
GB (7) | GB1133766A (no) |
IL (7) | IL24497A (no) |
IT (1) | IT1058251B (no) |
MY (2) | MY6700159A (no) |
NL (3) | NL6514178A (no) |
NO (2) | NO119948B (no) |
SE (4) | SE311160B (no) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3485840A (en) * | 1964-11-12 | 1969-12-23 | Hoffmann La Roche | 2,4-diamino - 5 - (2',4',5'-substituted benzyl) pyrimidines,intermediates and processes |
GB1142654A (en) * | 1965-10-28 | 1969-02-12 | Wellcome Found | Cyano-acetals and their use in benzylpyrimidine synthesis |
US3515783A (en) * | 1967-10-20 | 1970-06-02 | Hoffmann La Roche | Antibacterial composition containing 5-methyl - 3 - sulfanilamidoisoxazole and trimethoxybenzyl pyrimidine |
GB1261455A (en) * | 1969-03-06 | 1972-01-26 | Burroughs Wellcome Co | Improvements in or relating to substituted acrylonitriles |
DE2065367C2 (de) * | 1969-03-06 | 1985-04-04 | The Wellcome Foundation Ltd., London | Verfahren zur Herstellung von 2,4- Diamino-5-benzylpyrimidinen |
CH513181A (de) * | 1969-06-12 | 1971-09-30 | Hoffmann La Roche | Verfahren zur Herstellung von N-Oxyden von Benzylpyrimidinen |
US3996356A (en) * | 1969-07-02 | 1976-12-07 | Hoffmann-La Roche Inc. | Composition containing 5-sulfanilamido-3,4-dimethylisoxazole and a trimethoxybenzyl pyrimidine |
US3692787A (en) * | 1970-02-16 | 1972-09-19 | Burroughs Wellcome Co | Substituted 2,4-diamino-5-benzyl pyrimidines |
US3684810A (en) * | 1970-03-11 | 1972-08-15 | Hoffmann La Roche | Process for 2,4-diamino-5-(3,5-dimethoxy-4-hydroxybenzyl) pyrimidine |
US3993761A (en) * | 1971-12-01 | 1976-11-23 | Hoffmann-La Roche Inc. | Antibacterial compositions |
BE792096A (fr) * | 1971-12-01 | 1973-05-30 | Hoffmann La Roche | Nouvelles benzylpyrimidines |
BE795023A (fr) * | 1972-02-07 | 1973-08-06 | Hoffmann La Roche | Nouvelles benzylpyrimidines |
IT1044231B (it) * | 1972-03-16 | 1980-03-20 | Hoffmann La Roche | Combinazione di sostanze attive utile per combattere infezioni da batteri gram positivi e gran negativi |
DE2342213C3 (de) * | 1972-10-12 | 1979-10-18 | F. Hoffmann-La Roche & Co Ag, Basel (Schweiz) | Verwendung von potenzierten SuIf onamiden bei der Behandlung oder Verhinderung von Fischinfektionen |
ZA738760B (en) * | 1972-12-21 | 1974-08-28 | Hoffmann La Roche | Process for the manufacture of benzyl pyrimidines |
US4143227A (en) * | 1973-02-26 | 1979-03-06 | Hoffmann-La Roche Inc. | Process for substituted 5-benzyl-2,4-diamino-pyrimidines |
US3931181A (en) * | 1973-07-27 | 1976-01-06 | Hoffmann-La Roche Inc. | 2,4-Diamino-5-benzylpyrimidines |
CH591456A5 (no) * | 1973-09-12 | 1977-09-15 | Hoffmann La Roche | |
CH591457A5 (no) * | 1973-11-08 | 1977-09-15 | Hoffmann La Roche | |
US4076810A (en) * | 1973-11-08 | 1978-02-28 | Hoffmann-La Roche Inc. | Benzylpyrimidine antibacterial composition |
DK136470B (da) * | 1973-11-08 | 1977-10-17 | Hoffmann La Roche | Analogifremgangsmåde til fremstilling af 2,4-diamino-5-benzylpyrimidinderivater eller salte deraf. |
US4033962A (en) * | 1975-06-26 | 1977-07-05 | Hoffman-La Roche Inc. | 2,4-Diamino-pyrimidine derivatives and processes |
NL7609171A (nl) * | 1975-08-29 | 1977-03-02 | Hoffmann La Roche | Werkwijze voor het bereiden van antibacte- riele middelen. |
GB1582245A (en) * | 1976-06-09 | 1981-01-07 | Wellcome Found | Benzyl cyanoacetal derivatives and their conversion to pyrimidine derivatives |
DE2635765C3 (de) * | 1976-08-09 | 1979-02-08 | Ludwig Heumann & Co Gmbh, 8500 Nuernberg | Verfahren zur Herstellung von 2,4-EMamino-5-(3',4'r5'-trimethoxybenzyl)-pyrimidin |
LU77364A1 (no) * | 1977-05-18 | 1979-01-19 | ||
JPS55102517A (en) * | 1979-01-30 | 1980-08-05 | Shionogi & Co Ltd | Preparation of sulfamethoxazole-trimethoprim complex for administration via body cavity |
DE2944145A1 (de) * | 1979-11-02 | 1981-05-14 | Dynamit Nobel Ag, 5210 Troisdorf | Verfahren zur herstellung von 2,4-diaminopyrimidin |
JPS57109713A (en) * | 1980-12-26 | 1982-07-08 | Shionogi & Co Ltd | Pharmaceutical preparation of combined agent of sulfamethoxazole and trimethoprim for medication through celom |
IT1138146B (it) * | 1981-08-11 | 1986-09-17 | Proter Spa | Processo per la produzione della 2,4-diammino-(3,5-dimetossi-4-metos sietossi-benzil)-pirimidina |
FI64427C (fi) * | 1982-05-13 | 1989-11-08 | Uponor Nv | Lattiakaivo tai muu kuppimainen vesilukko. |
HU197670B (en) * | 1986-02-28 | 1989-05-29 | Egyt Gyogyszervegyeszeti Gyar | Process for producing composition comprising 2,4-diamino-5-(3,4-dimethoxybenzyl)-pyrimidine or pharmaceutically suitable acid addition salt thereof as active ingredient |
FR2595697B1 (fr) * | 1986-03-13 | 1988-07-08 | Rousselot Cie | Derives de benzyl-pyrimidine, leur procede de preparation ainsi que les compositions en contenant |
US4857651A (en) * | 1987-07-29 | 1989-08-15 | American Cyanamid Company | α-(2,3-Di(C1 -C4 alkoxy)ethylamino)-β-cyanostyrene and β-nitrostyrene compounds useful as intermediates in the preparation of insecticidal, acaricidal and nematicidal arylpyrroles and method for the preparation thereof |
US4996198A (en) * | 1988-07-11 | 1991-02-26 | Hoffmann-La Roche Inc. | Anticoccidial composition |
US5135924A (en) * | 1989-01-03 | 1992-08-04 | Hoffmann-La Roche Inc. | Therapeutic treatment of animals with oral administration of ormetoprim-potentiated sulfonamides |
US5158979A (en) * | 1989-04-19 | 1992-10-27 | New York University | Method and compositions for treating pneumocystic carini infections |
US5258373A (en) * | 1991-07-17 | 1993-11-02 | Hoffmann-La Roche Inc. | Anticoccidial compositions |
DE4333688C2 (de) * | 1993-10-02 | 2003-11-06 | Guenter Ege | Verfahren zur Herstellung von 3-Aryl-2-(dialkoxymethyl)-propannitrilen und ihre Umsetzung zu 5-Arylmethyl-2,4-diamino-pyrimidinen, insbesondere zu Trimethoprim |
US5514681A (en) * | 1994-08-17 | 1996-05-07 | Virginia Tech Intellectual Properties, Inc. | Compositions and methods for controlling pest insects |
TW438796B (en) * | 1996-05-15 | 2001-06-07 | Hoffmann La Roche | 2,4-diaminopyrimidine derivatives, the manufacture process thereof, and the antibiotically-active pharmaceutical composition containing the same |
US20090162858A1 (en) * | 2007-09-18 | 2009-06-25 | Cornish Virginia W | Orthogonal chemical inducer of dimerization |
CA2703261C (en) * | 2007-10-29 | 2013-10-08 | Nippon Suisan Kaisha, Ltd. | Antiparasitic agent for fish and method of controlling proliferation of fish parasites |
TWI429397B (zh) * | 2009-04-27 | 2014-03-11 | Nippon Suisan Kaisha Ltd | 含有葉酸合成抑制劑及/或葉酸活性化抑制劑之組成物的用途 |
FR3049861A1 (fr) | 2016-04-07 | 2017-10-13 | Univ Claude Bernard Lyon | Nouvelles compositions antivirales pour le traitement de la grippe |
CN106083653A (zh) * | 2016-06-06 | 2016-11-09 | 江苏天和制药有限公司 | 奥美普林中间体肉桂腈的合成方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3049544A (en) * | 1962-08-14 | Method for the preparation of | ||
US2628236A (en) * | 1953-02-10 | S-benzyl | ||
US2658897A (en) * | 1951-06-27 | 1953-11-10 | Burroughs Wellcome Co | 2, 4-diamino-5-benzyl pyrimidines |
GB734801A (en) * | 1953-03-06 | 1955-08-10 | Wellcome Found | Improvements in and relating to derivatives of pyrimidine and the manufacture thereof |
US2783178A (en) * | 1954-06-22 | 1957-02-26 | American Scient Lab Inc | Stable concentrated sulfaquinoxaline solutions and method for preparing |
US2823160A (en) * | 1955-03-29 | 1958-02-11 | Whitmoyer Lab Inc | Substituted pyrimidines compositions for chemotherapy of coccidiosis |
US2909522A (en) * | 1957-02-21 | 1959-10-20 | Burroughs Wellcome Co | Trialkoxybenzylpyrimidines and method |
DE1303727B (de) * | 1959-09-03 | 1976-02-05 | Ausscheidung aus: 14 45 176 The Wellcome Foundation Ltd., London | Alpha-Arylidensubstituierte Propioni-Irile |
US3085937A (en) * | 1960-11-21 | 1963-04-16 | Shionogi & Co | Method of combating coccidiosis with sulfonamide compositions |
US3485840A (en) * | 1964-11-12 | 1969-12-23 | Hoffmann La Roche | 2,4-diamino - 5 - (2',4',5'-substituted benzyl) pyrimidines,intermediates and processes |
-
1965
- 1965-05-07 US US454172A patent/US3485840A/en not_active Expired - Lifetime
- 1965-06-02 US US460834A patent/US3461206A/en not_active Expired - Lifetime
- 1965-07-09 US US470917A patent/US3341541A/en not_active Expired - Lifetime
- 1965-10-15 CH CH1427165A patent/CH467784A/de unknown
- 1965-10-20 DE DE19651545966 patent/DE1545966A1/de active Pending
- 1965-10-21 IL IL24497A patent/IL24497A/en unknown
- 1965-10-21 IL IL24498A patent/IL24498A/xx unknown
- 1965-10-22 CH CH1464865A patent/CH467270A/de unknown
- 1965-10-25 DE DE1545967A patent/DE1545967C3/de not_active Expired
- 1965-10-27 IL IL6532696A patent/IL32696A/en unknown
- 1965-10-27 IL IL32697A patent/IL32697A/xx unknown
- 1965-10-27 IL IL24534A patent/IL24534A/xx unknown
- 1965-10-27 IL IL32694A patent/IL32694A/xx unknown
- 1965-10-27 IL IL6532695A patent/IL32695A/xx unknown
- 1965-10-28 DK DK554065AA patent/DK125553B/da unknown
- 1965-10-30 FR FR36822A patent/FR5411M/fr not_active Expired
- 1965-11-01 FI FI2606/65A patent/FI43251B/fi active
- 1965-11-02 NL NL6514178A patent/NL6514178A/xx unknown
- 1965-11-05 GB GB46936/65A patent/GB1133766A/en not_active Expired
- 1965-11-05 GB GB58792/67A patent/GB1132084A/en not_active Expired
- 1965-11-05 GB GB46937/65A patent/GB1062508A/en not_active Expired
- 1965-11-05 GB GB58794/67A patent/GB1132086A/en not_active Expired
- 1965-11-05 GB GB58791/67A patent/GB1132083A/en not_active Expired
- 1965-11-05 GB GB46935/65A patent/GB1132082A/en not_active Expired
- 1965-11-05 GB GB58793/67A patent/GB1132085A/en not_active Expired
- 1965-11-08 BE BE671982D patent/BE671982A/xx unknown
- 1965-11-08 BE BE671983D patent/BE671983A/xx not_active IP Right Cessation
- 1965-11-08 NL NL6514472A patent/NL6514472A/xx unknown
- 1965-11-08 BE BE671981D patent/BE671981A/xx unknown
- 1965-11-09 BR BR174670/65A patent/BR6574670D0/pt unknown
- 1965-11-09 BR BR174667/65A patent/BR6574667D0/pt unknown
- 1965-11-09 BR BR174668/65A patent/BR6574668D0/pt unknown
- 1965-11-11 NO NO160436A patent/NO119948B/no unknown
- 1965-11-11 DK DK581065AA patent/DK115847B/da unknown
- 1965-11-11 NO NO160437A patent/NO115741B/no unknown
- 1965-11-12 IT IT25233/65A patent/IT1058251B/it active
- 1965-11-12 SE SE14668/65A patent/SE311160B/xx unknown
- 1965-11-12 NL NL6514743.A patent/NL163213C/xx not_active IP Right Cessation
- 1965-11-12 SE SE14670/65A patent/SE326185B/xx unknown
- 1965-11-12 SE SE3420/69A patent/SE346314B/xx unknown
- 1965-11-12 SE SE14669/65A patent/SE327122B/xx unknown
-
1967
- 1967-12-31 MY MY1967159A patent/MY6700159A/xx unknown
-
1972
- 1972-12-30 MY MY71/72A patent/MY7200071A/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO115741B (no) | ||
US3697512A (en) | 5-benzyl pyrimidines intermediates | |
US20160280663A1 (en) | 5-fluoro-4-imino-3-(alkyl/substituted alkyl)-1-(arylsulfonyl)-3,4-dihydropyrimidin-2(1h)-one and processes for their preparation | |
US4140793A (en) | Guanidine derivatives | |
CN1989111A (zh) | 生产3-苯基(硫代)尿嘧啶和二硫代尿嘧啶的方法 | |
SU548207A3 (ru) | Способ получени производных 2-ариламино-2-имидазолина или их солей | |
JPS6354714B2 (no) | ||
DK175838B1 (da) | Fremgangsmåde til fremstilling af 2,6-dichlordiphenylamineddikesyrederivater | |
US3855265A (en) | 5-benzyl pyrimidines intermediates therefore, and method | |
SU571189A3 (ru) | Способ получени бензилпиримидинов или их солей | |
NO138338B (no) | Fremgangsmaate til fremstilling av tresponplater med kondensasjonsharpikser som bindemiddel | |
SU1052158A3 (ru) | Способ получени производных пиримидилхиназолина или их солей (его варианты) | |
US3852276A (en) | 5-benzyl pyrimidines intermediate therefore, and method | |
US3850927A (en) | 5-benzyl pyrimidines intermediates therefore,and method | |
US4052553A (en) | 5-benzyl pyrimidines intermediates therefore, and method | |
US3849470A (en) | 5-benzyl pyrimidines intermediates therefore,and method | |
US3956327A (en) | Method of preparing 2,4-diamino-5-benzyl pyrimidines | |
US3991050A (en) | Preparation of β-Amino-α-benzylacrylonitriles | |
CA2087880C (en) | N-5-protected 2,5-diamino-4,6-dichloropyrimidines and process for their production | |
US3878252A (en) | Ring substituted beta-hydroxy-phenyethylmethyl sulphone or sulphoxide | |
JPS6119628B2 (no) | ||
US3849407A (en) | 5-benzyl pyrimidines intermediates | |
US4146713A (en) | Method of preparing 3-morpholino-2-cyanoacrylamide | |
US3507958A (en) | Compositions and methods of treating bacteria with cyclopropyl-2-sulphanilamido-pyrimidines | |
US3950378A (en) | Preparation of β-anilino-α-benzylacrylonitriles |